|Project Title||Investments in Infrastructure for Diverse Research Resources and the Health of the Public|
Wednesday, May 8, 2013
This article discusses 1) active surveillance of drugs and devices in the postmarket setting as an essential component of the lifecycle approach to drug evaluation and 2) creation of the FDA’s Sentinel Initiative, including the Mini-Sentinel pilot program, for postmarket risk identification and analysis.
- Vaccines, Blood & Biologics
- Devices and Radiologic Health